Last updated: July 15, 2026
ecutive summary
Supernus Pharmaceuticals, Inc. v. Zydus Pharmaceuticals (USA) Inc., 1:21-cv-07795 (D.N.J.) centers on Hatch-Waxman patent challenges tied to Zydus seeking FDA approval for a Supernus product. The case posture indicates a Paragraph IV-driven dispute, with Supernus asserting infringement and Zydus contesting validity and/or noninfringement. A complete, citation-grade litigation summary requires the docket’s substantive filings (complaint, answers, infringement contentions, invalidity contentions, claim constructions, and any settlement/entry of final judgments).
Litigation docket overview: Supernus v. Zydus (USA) Inc. 1:21-cv-07795
No litigation summary can be produced to the level required for professional decision-making because the record content is not provided: the complaint’s asserted patents, the asserted drug/product identifiers, the asserted claims, and the procedural milestones are not present in the prompt.
What patents are at issue in Supernus v. Zydus 1:21-cv-07795?
A complete answer requires the asserted patent numbers and their listed claims. Without the docket documents, there is no basis to list the specific patents, expiration dates, or legal theories (infringement, inducement, contributory infringement).
Which Orange Book-listed patents drive the dispute?
This requires the Orange Book entry for the relevant Supernus product and the patents Zydus challenged via Paragraph IV. The prompt does not identify the Orange Book listing(s) or the dosage form(s) implicated.
Are method-of-use or formulation patents asserted?
Determining whether the case includes method-of-use (use patents), formulation (composition/polymorph/excipients), or manufacturing method claims requires the complaint and Supernus infringement contentions. Those are not included.
What is Zydus challenging in the Paragraph IV framework?
A proper analysis requires: (1) the ANDA/BLA application reference product, (2) the specific patents asserted to be invalid, unenforceable, and/or not infringed, and (3) Zydus’s defenses and counterclaims. The prompt includes only the caption and docket number.
Is the dispute about validity (35 USC 102/103/112), noninfringement, or both?
The claim-level invalidity grounds and noninfringement theories must come from the responsive pleading and invalidity contentions. Without those filings, no credible breakdown is possible.
What is the likely venue and case management posture?
While the caption indicates a federal action, the key posture facts (claim construction schedule, trial setting, motions resolved) require docket entries.
When does Supernus v. Zydus reach key litigation milestones?
To summarize timing, a timeline of docket events is needed, including:
- complaint filing date
- service and answer date
- Rule 16 scheduling order
- infringement contentions
- invalidity contentions
- claim construction (Markman) dates and rulings
- dispositive motions
- any settlement and consent judgment dates
- final judgment or dismissal entry
None of these dates are provided, so no factual timeline can be generated.
How do courts typically handle claim construction in ANDA patent cases?
This question can’t be answered for this case without the actual Markman record (construed terms, doctrine of equivalents findings, means-plus-function interpretations, etc.). General statements would not satisfy the requested litigation-specific summary.
What is the settlement and generic launch risk for Zydus under 1:21-cv-07795?
Settlement and launch risk must be tied to:
- any FTC/consent decree terms
- any district court stay/lift provisions
- dismissal orders and dates
- FDA approval status and labeling carve-outs
- trigger dates for launch after dismissal or infringement/noninfringement judgments
Those facts are not included in the prompt.
Which other cases or consolidated litigations involve Supernus or Zydus?
A litigation landscape assessment needs cross-case citations, related dockets, and prior/parallel actions in the same district. The prompt provides only one docket number.
Key outcomes that would matter to investors and licensing teams
A decision-useful summary must identify which of these occurred:
- patents found invalid
- patents found not infringed
- partial claim construction favorable to either party
- injunction granted or denied
- dismissal with/without prejudice
- settlement amount and effective date
- stipulations that affect future Paragraph IV filings
Those outcomes are not available from the prompt.
Key Takeaways
- The docket identifier (1:21-cv-07795) is provided, but the substantive record needed for a litigation-grade summary is not present.
- No asserted patent list, claim scope, invalidity theories, procedural milestones, or judgment/settlement outcomes can be stated reliably without the underlying docket filings.
FAQs
- What patents did Supernus assert in 1:21-cv-07795?
- Did the court issue a Markman claim construction in Supernus v. Zydus, and what terms were construed?
- Was there a Paragraph IV settlement, and did it include an agreed-upon entry or launch date?
- Which defenses did Zydus raise: invalidity under 35 USC 102/103/112, unenforceability, or noninfringement?
- What FDA approval status did the parties reference in briefing for 1:21-cv-07795?
References (APA)
- Supernus Pharmaceuticals, Inc. v. Zydus Pharmaceuticals (USA) Inc., No. 1:21-cv-07795 (D.N.J.).
